Q1. In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with:
a. Bevacizumab (Avastin)
b. Dacarbazine (DTIC)
c. Trametinib (Mekinist)
d. Dabrafenib (Tafinlar)
e. Ipilimumab (Yervoy)
f. Vemurafenib (Zelboraf)
g. Nivolumab (Opdivo)
h. Nivolumab + Ipilimumab (Opdivo + Yervoy)
i. Pembrolizumab (Keytruda)
j. Vemurafenib + cobimetinib (Zelboraf + Cotellic)
k. Dabrafenib + Trametinib (Tafinlar + Mekinist)
l. Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients
m. Other active systemic anti-cancer therapy [please state]
n. Palliative care only
Q2. In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following:
a. Ipilimumab
b. Ipilimumab AND Nivolumab
c. Nivolumab
d. Pembrolizumab
e. Dabrafenib AND Trametinib
f. Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
g. Other active systemic anti-cancer therapy
h. Palliative care only